To the Editor:
Autosomal recessive hypercholesterolemia (ARH) is a rare Mendelian dyslipidemia characterized by markedly elevated plasma low-density lipoprotein (LDL) cholesterol levels. ARH is caused by mutations in a protein that contains a phosphotyrosine binding domain (PTB) required for internalization of LDL in the liver. 1, 2 LDL receptor function is defective in liver and lymphocytes but not in fibroblasts from ARH patients. We reported a Syrian ARH family earlier in Circulation Research and identified a mutation in the splice-acceptor site of intron 1 that converts the guanine of AG into cytosine AC. 3 Splice mutations may cause cryptic site activation, intron retention, creation of new splice sites, or exon skipping. 4 However, we had no access to ARH gene-expressing tissue. We therefore constructed ARH gene fragments from an affected and a nonaffected individual and transfected the fragments into hepatocellular carcinoma cells (HEPG2).
DNA fragments containing the 3Ј part of intron 1, exon 2, the entire intron 2, exon 3, and the 5Ј part of intron 3 were PCRamplified from nonaffected and affected probands. Both fragments were subcloned into TOPO-XL vector (Invitrogen). Fragments containing the 5Ј noncoding part of exon 1, exon 1, and the 5Ј part of intron 1 were also amplified and were subcloned upstream to the previously cloned fragment. The final partial ARH gene, with and without mutation, was cloned into phCMV3/Xi expression vector (Gene Therapy Systems, San Diego, Calif). We did not include the entire intron 1 because we were concerned that the entire intron could be retained upon ARH gene transcription when the spliceacceptor site of intron 1 is mutated. Amplifying the final transcript from the cDNA would be extremely difficult because intron 1 is about 6 kb. We included only the 5Ј and 3Ј parts of intron 1 in our constructs including the necessary sequences for splicing. The final fragments are shown in the Figure (top). The ARH gene cDNA was cloned into the same expression vector as a control.
We chose HEPG2 cells as a transfection target to resemble in vivo conditions. Transfection was optimized using Effectene (Qiagen) as a transfection reagent; 40% to 50% transfection rates were obtained. HEPG2 cells were transfected with the expression vectors containing constructed fragments from wild-type and mutant constructs, with both constructs, and with the ARH gene cDNA construct. Three days after transfection, the cells were harvested, total RNAs were extracted, and the transcripts from the transfected constructs were amplified by RT-PCR. We used primers that bind to sequences in exon 1 and to the polyadenylation signal in the vector.
A band of Ϸ1100 bp came up from cDNA produced from the transfected ARH gene. This band confirms that the transfected ARH gene was properly transcribed. Using the same primers to amplify the transcripts produced from the transfected wild-type and mutant constructs resulted in two similar 600-bp bands. Direct sequencing revealed that these transcripts consisted of exon 1, exon 2, exon 3 with the 5Ј end of intron 3, and the polyadenylation sequence in the vector, see Figure ( middle). The presence of the 5Ј end of intron 3 in the final transcript is due to the lack of splice-acceptor signal in intron 3, since the 3Ј end of intron 3 is not included in the construct. The fact that our wild-type construct was spliced correctly, exactly the same way the whole ARH gene appears in vivo, indicates that the sequences contained in our constructs were sufficient for normal splicing to take place and that no splice-activating sequences were missing in these constructs. The transcripts produced from HEPG2 cells transfected with the wild-type and both constructs, namely the wild-type and the mutant, produced the same signals. The only difference between the wild-type and mutant bands was the deletion of two nucleotides in the beginning of exon 2, namely AG (Figure,  bottom) .
The last 10 bases at the 3Ј part of intron 1 are GCTACCCCAG. Exon 2 in the ARH gene again begins with AG. When the last G in intron 1 is mutated to C, the adjacent AG in the beginning of exon 2 is recognized by the spliceosome as a new splice-acceptor site and splicing of intron 1 will take place at this position. Thus, AG bases in the beginning of exon 2 will no longer belong to the coding sequence, leading to a frame-shift mutation. The mutation changes Top, Constructed fragments prepared for testing the splice profile in the wild-type and the mutant fragments. The constructed fragments consisted of the 5Ј of the noncoding part of exon 1, exon 1, 5Ј intron 1, 3Ј intron 1, exon 2, intron 2, exon 3, and 5Ј intron 3. Middle, Final transcripts. The transcripts were amplified by primers that bind to sequences in exon 1 and to polyA signal in the vector. The amplified transcripts from both, the wild-type and mutant, constructs were the same about Ϸ600 bp. Bottom, Sequence comparison of the wild-type and the mutant at the site of deletion. Filled boxes are exons, and lines represent introns. A portion of the intron 1 sequence was not included, as represented by vertical lines.
the subsequent reading frame and leads to the appearance of the stop codon TGA just two codons later. The resulting truncated protein will consist only of 32 amino acids, leaving out the entire PTB domain. The domain is crucial for LDLR internalization.
The mammalian 3Ј splice site consensus can be divided into two parts. One is a highly conserved YAG, where Y is a pyrimidine, at positions Ϫ1 to Ϫ3 relative to the site of exon ligation. At position Ϫ4, any nucleotide can be present. Another part is a polypyrimidine tract (PPT), which starts from position Ϫ5 and extends for 10 or more nucleotides back into the intron. 5 The sequence context in the vicinity of the mutated splice site brought the AG at the beginning of exon 2 as an ideal splice-acceptor site (Figure 1, top) . First, AG is present in the beginning of exon 2 immediately adjacent to the original splice site. Second, the splice-acceptor mutation in our family converted the guanine into cytosine at the original 3Ј splice site. This cytosine occupies the position Ϫ3 in the newly emerged splice site and is consistent with the consensus sequence of 3Ј splice site. This context helped to create a new 3Ј splice site of intron 1 that is perfectly in line with the 3Ј consensus splice site.
The use of the new 3Ј splice site at the beginning of exon 2 was also predicted when we analyzed the available sequence from intron 1 with exon 1 and exon 2. We used the splice-finder software (http://www.genet.sickkids.on.ca/‫ف‬ali/splicesitefinder.html). The scores of the original splice-acceptor site and the new site that emerged subsequent to the AC mutation are almost the same (83.7 versus 83) as calculated by the program. Had the mutation converted the G of AG into T or A, the splice-finder program would also recognize the adjacent AG in the beginning of exon 2 as a candidate for splicing, but with lower scores, 74.7 and 71.6, respectively, versus 83.7.
The consequences of the splice mutation are due to a deletion of two bases from the beginning of exon 2 resulting in a frame-shift mutation leading to a truncated protein. In this report, we verify how the mutation we described earlier causes protein malfunction. 3 The approach we used serves as a paradigm to study splice profiles when no patient tissues or cells are available.
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